Aeolus Form 8-K - Multiple Dose Safety Study Results
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of
Report (Date of earliest event reported): March 22, 2007
AEOLUS
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
(State
or
other jurisdiction of incorporation)
0-50481
56-1953785
(Commission
File Number) (IRS
Employer ID Number)
23811
Inverness Place
Laguna
Niguel, California 92677
(Address
of Principal Executive Offices, Including Zip Code)
949-481-9825
(Registrant’s
Telephone Number, Including Area Code)
__________________
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
£ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
£ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
| |
£
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
| £ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
Item
7.01 Regulation FD Disclosure.
On
March
22, 2007, Aeolus Pharmaceuticals, Inc. (“Aeolus”) reported the results of its
multiple dose safety study of AEOL 10150 in patients with Amyotrophic Lateral
Sclerosis (“ALS” or “Lou Gehrig’s disease”).
A
copy of
the press release issued by Aeolus on March 22, 2007 announcing this event
is
attached as Exhibit 99.1 to this Current Report on Form 8-K.
Item
9.01. Financial Statements and Exhibits.
| |
Exhibit
99.1
|
|
Press
release dated March 22, 2007
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this Report to be signed on its behalf by the undersigned thereunto
duly authorized.
AEOLUS
PHARMACEUTICALS, INC.
Date:
March 22, 2007
/s/
Michael P. McManus___________________
Michael
P. McManus
Chief
Financial Officer, Treasurer and Secretary